Clinical Research Directory
Browse clinical research sites, groups, and studies.
Anti-cancer DC Cell Vaccination to Treat Solid Tumors
Sponsor: Second Affiliated Hospital of Guangzhou Medical University
Summary
Placental or tumor-derived heat shock protein gp96 is collected, purified, and stored. The DC cells are isolated from the patient's blood and then cocultured with the gp96 to obtain the activated DC cell product. The manufactured DC cells are subcutaneously or intra-tumor injected into the patient. Clinical studies will be performed to test anti-cancer function of the DC vaccination for immunotherapy of cancer patients. In this phase I study, the safety, tolerance, and preliminary efficacy of the DC vaccine immunotherapy on advanced cancers will firstly be evaluated.
Official title: Anti-cancer DC Cell Vaccination to Treat Advanced Solid Tumors: Phase I Clinical Trial
Key Details
Gender
All
Age Range
18 Years - 80 Years
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2024-06-05
Completion Date
2035-12-30
Last Updated
2024-06-27
Healthy Volunteers
No
Conditions
Interventions
DC cell Vaccine
Deliver DC cell vaccine into patients for anti-ancer therapy.
Locations (1)
The Second Affiliated Hospital of Guangzhou Medical University
Guanzhou, Guangdong, China